NKG: Posterior Cervical Screw System
What it covers
Posterior cervical screw systems are intended for use in fusion procedures of the cervical spine and/or craniocervical junction and/or cervicothoracic junction for: 1) spinal fractures and dislocations; 2) deformities; 3) instabilities; 4) failed previous fusions; 5) tumors; 6) inflammatory disorders; 7) spinal degeneration, 8) facet degeneration with instability; and 9) reconstruction following decompression to treat radiculopathy and/or myelopathy. These systems are also intended to stabilize the spine in the absence of fusion for a limited time period in patients with tumors involving the cervical spine in whom life expectancy is of insufficient duration to permit achievement of fusion.
FDA’s definition of product code NKG, from the Product Classification database.
FDA flags NKG devices as implants.
Recent clearances
| 510(k) | Device | Applicant | Decision | Type |
|---|---|---|---|---|
| K254260 | The VEGA Cervical Screw System | GS Medical Co., Ltd. | Sep 17, 2026 | Traditional |
| K253195 | TAURUS Posterior Occipital-Cervico-Thoracic Spinal Systems | ZheJiang Decans Medical Devices Co., Ltd. | Jun 2, 2026 | Traditional |
| K254045 | CarboClear® Posterior Cervical Screw System; CarboClear® Hybrid Posterior Cervical Screw System | CarboFix Orthopedics , Ltd. | Mar 16, 2026 | Traditional |
| K254165 | Infinity OCT System | Medtronic Sofamor Danek USA, Inc. | Jan 21, 2026 | Special |
| K252327 | CMORE® CT System; CMORE® CT System Navigated Instruments | Icotec AG | Nov 12, 2025 | Traditional |
| K253129 | Infinity OCT System | Medtronic Sofamor Danek USA, Inc. | Oct 24, 2025 | Special |
| K251725 | ANAX OCT Spinal System | Cg Medtech Co., Ltd. | Jun 25, 2025 | Special |
| K250866 | Sovereign Posterior Cervical System | Met One Technologies, LLC | May 20, 2025 | Traditional |
| K242674 | Freedom Posterior Cervical Screws | Signature Orthopaedics Pty, Ltd. | May 13, 2025 | Traditional |
| K250332 | Virage® OCT Spinal Fixation System | Highridge Medical, LLC | Apr 4, 2025 | Traditional |
Clearances by year
119 NKG 510(k)s were cleared from 2011 to Oct 29, 2026. Days to decision run from the day FDA received the 510(k) to its decision, including time on hold.
| Year | Clearances | Median days to decision |
|---|---|---|
| 2026 (so far) | 4 | 169 |
| 2025 | 6 | 58 |
| 2024 | 3 | 100 |
| 2023 | 10 | 58 |
| 2022 | 7 | 108 |
| 2021 | 7 | 56 |
| 2020 | 14 | 59 |
| 2019 | 8 | 50 |
| 2018 | 12 | 61 |
| 2017 | 15 | 108 |
| 2016 | 16 | 87 |
| 2015 | 17 | 71 |
Who submits
63 applicants cleared a NKG device since 2011. 68% of the clearances went to applicants in United States, then Switzerland (13%), South Korea (7%) and France (4%). By type: Traditional 81% and Special 19%.
| Applicant | Clearances since 2011 |
|---|---|
| Medtronic Sofamor Danek USA, Inc. | 7 |
| Orthofix, Inc. | 7 |
| Medacta International S.A. | 6 |
| Medos International SARL | 6 |
| Nu Vasive, Incorporated | 6 |
| Globus Medical, Inc. | 4 |
| L&K BIOMED Co., Ltd. | 4 |
| Life Spine, Inc. | 4 |
How FDA classifies it
Class II (special controls). The special controls for posterior cervical screw systems are:
(1) The design characteristics of the device, including engineering schematics, must ensure that the geometry and material composition are consistent with the intended use.
(2) Nonclinical performance testing must demonstrate the mechanical function and durability of the implant.
(3) Device components must be demonstrated to be biocompatible.
(4) Validation testing must demonstrate the cleanliness and sterility of, or the ability to clean and sterilize, the device components and device-specific instruments.
(5) Labeling must include the following:
(i) A clear description of the technological features of the device including identification of device materials and the principles of device operation;
(ii) Intended use and indications for use including levels of fixation;
(iii) Device specific warnings, precautions, and contraindications that include the following statements:
(A) “Precaution: Preoperative planning prior to implantation of posterior cervical screw systems should include review of cross-sectional imaging studies (e.g., CT and/or MRI) to evaluate the patient's cervical anatomy including the transverse foramen, neurologic structures, and the course of the vertebral arteries. If any findings would compromise the placement of these screws, other surgical methods should be considered. In addition, use of intraoperative imaging should be considered to guide and/or verify device placement, as necessary.”
(B) “Precaution: Use of posterior cervical pedicle screw fixation at the C3 through C6 spinal levels requires careful consideration and planning beyond that required for lateral mass screws placed at these spinal levels, given the proximity of the vertebral arteries and neurologic structures in relation to the cervical pedicles at these levels.”
(iv) Identification of magnetic resonance (MR) compatibility status;
(v) Cleaning and sterilization instructions for devices and instruments that are provided non-sterile to the end user, and;
(vi) Detailed instructions of each surgical step, including device removal.
From 21 CFR 888.3075. Special controls are the requirements a 510(k) must show it meets.
Standards
21 CFR 888.3075 names no consensus standards. Check FDA’s recognized standards database, or ask which standards recent NKG clearances declared.
Ask about NKG
Questions about NKG
What is FDA product code NKG?
Product code NKG, “Posterior Cervical Screw System” in FDA's classification database, is a Class II device type under 21 CFR 888.3075 (posterior cervical screw system), reviewed by FDA's Orthopedic panel. FDA's 510(k) database lists 119 clearances under NKG, 119 of them since 2011.
How many 510(k) clearances are there under NKG?
FDA’s 510(k) database listed 119 clearances under NKG as of Oct 29, 2026, 119 of them decided since 2011; the most recent decision was Sep 17, 2026. The Predicate Finder searches the live database.
How long does FDA take to clear a NKG 510(k)?
For the 11 NKG clearances decided in the two years before Oct 29, 2026, the median time from FDA receiving the 510(k) to its decision was 88 days. That counts calendar days, including time the submission was on hold waiting for answers from the submitter.
Which companies have the most NKG clearances?
Since 2011: Medtronic Sofamor Danek USA, Inc. (7), Orthofix, Inc. (7), Medacta International S.A. (6), Medos International SARL (6) and Nu Vasive, Incorporated (6). 63 applicants have cleared a NKG device in that time.